Last reviewed · How we verify

DHEA treatment — Competitive Intelligence Brief

DHEA treatment (DHEA treatment) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Steroid hormone / Hormone replacement. Area: Endocrinology / Aging / Immunology.

phase 3 Steroid hormone / Hormone replacement Androgen receptor, Estrogen receptor (indirect via metabolite conversion) Endocrinology / Aging / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

DHEA treatment (DHEA treatment) — University Hospital, Bordeaux. DHEA (dehydroepiandrosterone) is an endogenous steroid hormone precursor that acts as a substrate for the synthesis of androgens and estrogens, modulating hormonal balance and immune function.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DHEA treatment TARGET DHEA treatment University Hospital, Bordeaux phase 3 Steroid hormone / Hormone replacement Androgen receptor, Estrogen receptor (indirect via metabolite conversion)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Steroid hormone / Hormone replacement class)

  1. University Hospital, Bordeaux · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DHEA treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/dhea-treatment. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing